Development of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c00897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Changkeun Im und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea. Hauptthemen laut MEDLINE: Cross-Linking Reagents, Radiopharmaceuticals, Trastuzumab, Aza Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Korea Institute of Radiological and Medical Sciences.
Abstract (Originalsprache)
Radioiodine has been exploited in nuclear medicine for diagnostic and therapeutic purposes in various diseases. There are two radioiodination methods for biomolecules, that is, (1) direct radioiodination of tyrosine or histidine residue in a biomolecule and (2) indirect radioiodination by using a prosthetic group, which bridges radioiodine and the biomolecule. While directly radioiodinated biomolecules suffer from deiodination in vivo, the most commonly used indirect labeling method based on N-succinimidyl-3-[*I]iodobenzoate has a problem of inconvenience due to an high-performance liquid chromatography (HPLC) purification process. To tackle both issues, a novel prosthetic click-linker-antibody conjugate (3-[123/125I]iodobenzoyl-PEG4-tetrazine-TCO-PEG4-trastuzumab (3-[123/125I]IBTTT)) with favorable radiochemical yield (>57%) and purity (>99%) was developed using a fluorous tin-based organotin precursor with streamlined purification process utilizing fluorous solid-phase extraction (FSPE) cartridge and spin column. In vitro binding studies demonstrated that 3-[125I]IBTTT maintained its biological activity with a KD value (5.606 nM) comparable to that of unmodified trastuzumab (5.0 nM). In vivo imaging of 3-[123I]IBTTT in a human epidermal growth factor receptor 2 (HER2)-expressing gastric cancer mouse model revealed favorable tumor accumulation and negligible thyroid uptake compared to directly radioiodinated trastuzumab ([123I]trastuzumab). It was also confirmed, by blocking experiments and a biodistribution study, that the tumor accumulation of 3-[123I]IBTTT was attributed to HER2-specific binding. In summary, we developed a novel radioiodinated prosthetic click-linker agent (3-[123/125I]IBTTT) with favorable radiochemical yield, purity, stability, and in vivo behavior, providing a highly promising tool for targeted imaging and potential therapy of HER2-positive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
- Radiological and Medico-Oncological Sciences, University of Science and Technology, Seoul 01812, Korea.
- Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.
- Department of Life Sciences, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea.
- Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
ORCID-Profile: Jae Hun Ahn, Yong Jin Lee, Choong Mo Kang
Förderung
- National Research Foundation of Korea
- Korea Institute of Radiological and Medical Sciences
Zitieren
APA
Im, C., Ahn, J. H., Lim, H., Kim, D., Lee, Y. J., Kang, C. S., & Kang, C. M. (2025). Development of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00897
Vancouver
Im C, Ahn JH, Lim H, Kim D, Lee YJ, Kang CS, et al. Development of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c00897
BibTeX
@article{Im2025,
author = {Im, Changkeun and Ahn, Jae Hun and Lim, Hwisoo and Kim, Dohyeon and Lee, Yong Jin and Kang, Chi Soo and Kang, Choong Mo},
title = {Development of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c00897}
}
EUVIMED